U.S. Plans To Use Toyama’s Favipiravir In Ebola Fight
This article was originally published in PharmAsia News
Executive Summary
The U.S. is urgently trying to obtain approval for the influenza drug favipiravir (T-705), developed by Fujifilm Holdings subsidiary Toyama Chemicals, for the treatment of Ebola hemorrhagic fever currently raging in West Africa.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.